This article is more than 5 years old. Information may no longer be current.
VIDEO: Patient selection, sizing, techniques important for bioresorbable vascular scaffold implantation
Click Here to Manage Email Alerts
WASHINGTON — In this Cardiology Today video perspective, B. Hadley Wilson, MD, FACC, chair-elect of the board of governors and secretary-elect of the board of trustees with the American College of Cardiology and interventional cardiologist at Sanger Heart & Vascular Institute in the Carolinas HealthCare System, provides his insight on new data from the ABSORB III trial of the bioresorbable vascular scaffold.
Results presented at the ACC Scientific Session highlighted an increased 2-year cumulative rate of target lesion failure with the bioresorbable vascular scaffold (Absorb BVS, Abbott Vascular) compared with an everolimus-eluting stent (EES; Xience, Abbott Vascular). However, the difference in TLF was smaller in patients with appropriately sized vessels.
“What [the researchers] looked at [was whether] some of the earlier concerns were actually improved upon with improving techniques with placement of BVS and with the selection of patients who received the BVS,” Wilson said.
He noted that the results are “encouraging for the BVS that when properly placed, selected and sized, and with proper implementation, that they will do as well as third-generation stents.”
Follow-up is ongoing, and Hadley said he looks forward to further results from the series of BVS trials.